Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
The iShares Neuroscience and Healthcare ETF (IBRN) focuses on companies within the neuroscience and broader healthcare sectors, providing exposure to firms engaged in the development of treatments for neurological disorders. Its competitive position is strengthened by a diversified portfolio of high-growth biotech and pharmaceutical companies, primarily located in North America and Europe.
IBRN generates revenue primarily through management fees based on the total assets under management, which are influenced by the performance of the underlying stocks in the ETF. The ETF's focus on high-growth sectors like neuroscience provides it with pricing power and a competitive advantage in attracting institutional and retail investors seeking exposure to innovative healthcare solutions.
Performance of underlying biotech stocks, particularly those focused on neurological treatments
Changes in healthcare policy impacting drug approvals and pricing
Market sentiment towards healthcare and biotech sectors
Mergers and acquisitions activity within the healthcare space
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Increased competition from other healthcare-focused ETFs
Market volatility affecting investor sentiment towards biotech stocks
Liquidity risk associated with underlying holdings in the ETF
Potential for high volatility in AUM due to market fluctuations
moderate - The healthcare sector is generally resilient during economic downturns, but biotech companies can be sensitive to funding availability and investor sentiment.
Higher interest rates may increase the cost of capital for biotech firms, potentially slowing innovation and affecting stock performance within the ETF.
minimal - The ETF is not directly dependent on credit markets, but the financial health of its underlying holdings can be impacted by credit conditions.
growth - Investors seeking exposure to high-growth biotech and healthcare sectors.
high - The ETF is likely to exhibit high volatility given the nature of its underlying assets.